New drug targets 'Undruggable' cancer mutation in first human trial
NCT ID NCT06715124
Summary
This is a first-in-human study to check the safety and early effectiveness of a new drug, QTX3544, for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The trial will test QTX3544 given alone or combined with an existing cancer drug, cetuximab, in about 237 adults who have already tried at least one other treatment. The main goals are to find the safest dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Center
Durham, North Carolina, 27705, United States
-
Florida Cancer Specialists & Research Institute
Sarasota, Florida, 34232, United States
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics Mountain Region, LLC
West Valley City, Utah, 84119, United States
-
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.